Fall Season Respiratory Vaccine Codes

Fall Season Respiratory Vaccine Codes

The current Fall vaccine code and crosswalk tables for COVID-19, RSV, and Influenza are provided in the following summary tables.

Fall 2023 COVID-19 Vaccine Codes and Crosswalks

The following table provides a preview and summary of the vaccine codes and crosswalks that will be activated if the FDA authorizes use and ACIP votes to recommend the candidate vaccines.

Note: Codes in the following table are effective and published in the full vaccine code sets only upon EUA issuance or BLA licensure of COVID-19 vaccine(s) by the Food and Drug Administration (FDA). Additional code details and fields values are included in the vaccine code sets once published.

Download the Fall 2023 COVID-19 Vaccine Code Crosswalk table

FALL 2023 COVID-19 CODES AND CROSSWALK
Manufacturer (MVX) Product Label Tradename (*) CVX Code CVX Term Description CVX Short Description NDC Virus Strain UoS NDC10
UoS NDC11
Packaging UoU NDC10
UoU NDC11
Age Cohort;
Presentation
CPT Code CPT Description
Pfizer
(PFR)
COMIRNATY (COVID-19 Vaccine, mRNA, 2023-2024 Formula) 309 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 30 mcg/0.3 mL dose COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL SARS-CoV-2 virus strain Omicron XBB.1.5 0069-2362-10
00069-2362-10
CARTON, 10 SINGLE-DOSE VIALS 0069-2362-01
00069-2362-01
Ages 12 years and older;
VIAL, SINGLE-DOSE, 30 mcg/0.3 mL
91320 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use
Pfizer
(PFR)
COMIRNATY (COVID-19 Vaccine, mRNA, 2023-2024 Formula), no freeze formulation 309 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 30 mcg/0.3 mL dose COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL SARS-CoV-2 virus strain Omicron XBB.1.5 0069-2377-10 00069-2377-10 CARTON, 10 PRE-FILLED GLASS SYRINGES 0069-2377-01 00069-2377-01 Ages 12 years and older;
GLASS SYRINGE, SINGLE-DOSE, 30 mcg/0.3 mL – DO NOT FREEZE
91320 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use
Pfizer
(PFR)
COMIRNATY (COVID-19 Vaccine, mRNA, 2023-2024 Formula) 309 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 30 mcg/0.3 mL dose COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL SARS-CoV-2 virus strain Omicron XBB.1.5 0069-2392-10
00069-2392-10
CARTON, 10 PRE-FILLED PLASTIC SYRINGES 0069-2392-01
00069-2392-01
Ages 12 years and older;
PLASTIC SYRINGE, PRE-FILLED, 30 mcg/0.3 mL
91320 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use
Pfizer
(PFR)
Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) 310 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 10 mcg/0.3 mL dose COVID-19, mRNA, LNP-S, PF, tris-sucrose, 10 mcg/0.3 mL SARS-CoV-2 virus strain Omicron XBB.1.5 59267-4331-2
59267-4331-02
CARTON, 10 SINGLE-DOSE VIALS 59267-4331-1
59267-4331-01
Ages 5 through 11 years;
VIAL, SINGLE-DOSE, 10 mcg/0.3 mL
91319 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use
Pfizer
(PFR)
Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) 308 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 3 mcg/0.3 mL dose COVID-19, mRNA, LNP-S, PF, tris-sucrose, 3 mcg/0.3 mL SARS-CoV-2 virus strain Omicron XBB.1.5 59267-4315-2
59267-4315-02
CARTON, 10 MULTI-DOSE VIALS 59267-4315-1
59267-4315-01
Ages 6 months through 4 years;
VIAL, MULTI-DOSE, 3 DOSES, 3mcg / 0.3 mL AFTER DILUTION
91318 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use
Novavax
(NVX)
Novavax COVID-19 Vaccine, Adjuvanted 313 SARS-COV-2 (COVID-19) vaccine, subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 5 mcg/0.5 mL dose COVID-19, subunit, rS-nanoparticle, adjuvanted, PF, 5 mcg/0.5 mL SARS-CoV-2 virus strain Omicron XBB.1.5 80631-105-02
80631-0105-02
CARTON, 2 MULTI-DOSE VIALS 80631-105-01
80631-0105-01
Ages 12 years and older;
VIAL, MULTI-DOSE, 5 DOSES, 5 mcg/0.5 mL
91304 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, for intramuscular use
Moderna
(MOD)
Spikevax 312 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL SARS-CoV-2 virus strain Omicron XBB.1.5 80777-102-95
80777-0102-95
CARTON, 10 SINGLE-DOSE VIALS 80777-102-04
80777-0102-04
Ages 12 years and older;
VIAL, SINGLE-DOSE, 50 mcg/0.5 mL
91322 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use
Moderna
(MOD)
Spikevax 312 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL SARS-CoV-2 virus strain Omicron XBB.1.5 80777-102-96
80777-0102-96
CARTON, 10 PRE-FILLED SYRINGES 80777-102-01
80777-0102-01
Ages 12 years and older;
SYRINGE, PRE-FILLED, 50 mcg/0.5 mL
91322 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use
Moderna
(MOD)
Spikevax 312 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL SARS-CoV-2 virus strain Omicron XBB.1.5 80777-102-93
80777-0102-93
CARTON, 10 BLISTER-SEALED PRE-FILLED SYRINGES 80777-102-01
80777-0102-01
Ages 12 years and older;
SYRINGE, PRE-FILLED, 50 mcg/0.5 mL
91322 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use
Moderna
(MOD)
Moderna COVID-19 Vaccine 311 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 25 mcg/0.25 mL dose COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mL SARS-CoV-2 virus strain Omicron XBB.1.5 80777-287-92
80777-0287-92
CARTON, 10 SINGLE-DOSE VIALS 80777-287-07
80777-0287-07
Ages 6 months through 11 years;
VIAL, SINGLE-DOSE, 25 mcg/0.25 mL
91321 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use

(*) Product Label Tradename: If the manufacturer name is included in the tradename, the vaccine product is to be provided under Emergency Use Authorization (EUA), once FDA EUA issuance is received. Other tradenames are for vaccine products to be provided under BLA licensure, once approved.

Other COVID-19 Vaccine Related Codes and Links

Information regarding currently active EUA Recipient and Caregiver Fact Sheet URLs and Codes can be found here.

Registered users can access COVID-19 vaccine lot numbers and expiration dates provided to CDC by the vaccine manufacturer.

Information regarding Previous COVID-19 pandemic Emergency Use Authorization (EUA) and BLA codes and crosswalks can be found here.

Respiratory Syncytial Virus (RSV) Codes and Crosswalks

The following table includes the RSV codes and crosswalks included in the CDC IIS Vaccine Code Sets. Note that the CPT codes shown are not mapped to the NDC codes, but are mapped to the CVX codes shown. CPT codes provided in the vaccine code sets are to assist with code categorizations and are not intended to represent billable codes.

Download the RSV Crosswalk table

Respiratory Syncytial Virus (RSV) Vaccine Codes Fall 2023
CVX Code CVX Description Sale Proprietary Name Sale Labeler MVX Code Unit of Sale NDC11 Unit of Use NDC11 Presentation CPT Code CPT Description
303 Respiratory syncytial virus (RSV), vaccine, recombinant, protein subunit RSV prefusion F, adjuvant reconstituted, 0.5 mL, preservative free Arexvy GlaxoSmithKline Biologicals SA SKB 58160-0848-11 58160-0723-03 VIAL, 0.5 mL, reconstituted 90679 Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use
305 Respiratory syncytial virus (RSV), vaccine, bivalent, protein subunit RSV prefusion F, diluent reconstituted, 0.5 mL, preservative free Abrysvo Pfizer Laboratories Div Pfizer Inc PFR 00069-0344-01
00069-0344-05
00069-0344-10
00069-0207-01 VIAL, 0.5 mL, reconstituted 90678 Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use
Respiratory Syncytial Virus (RSV) Monoclonal Antibody Codes Fall 2023 (*)
CVX Code CVX Description Sale Proprietary Name Sale Labeler MVX Code Unit of Sale NDC11 Unit of Use NDC11 Presentation CPT Code CPT Description
306 Respiratory syncytial virus (RSV) monoclonal antibody, IgG1κ, (nirsevimab-alip), 0.5 mL, neonates and children to 24 months BEYFORTUS Sanofi Pasteur Inc. PMC 49281-0575-15 49281-0575-00 SYRINGE, 0.5 mL 90380 Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use
307 Respiratory syncytial virus (RSV) monoclonal antibody, IgG1κ, (nirsevimab-alip), 1 mL, neonates and children to 24 months BEYFORTUS Sanofi Pasteur Inc. PMC 49281-0574-15 49281-0574-88 SYRINGE, 1 mL 90381 Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for intramuscular use

(*) The BEYFORTUS nirsevimab monoclonal antibody codes are included in the vaccine code set in a manner similar to regular vaccines to enable reporting or other program data exchange in accordance with ACIP and CDC guidelines.

Respiratory Syncytial Virus (RSV) Unspecified Codes
CVX Code CVX Description CVX Note
314 Respiratory syncytial virus (RSV) vaccine, unspecified Unspecified, for historic records where the specific vaccine administered is not known
315 Respiratory syncytial virus (RSV) monoclonal antibody (MAB), unspecified Unspecified, for historic records where the specific RSV MAB administered is not known
304 Respiratory syncytial virus (RSV), unspecified Unspecified, for historic records where it is not known if RSV vaccine or RSV MAB was administered

Guidance relating to RSV vaccines can be found at Home page for MMWR | MMWR (cdc.gov)

On July 17, 2023, the Food and Drug Administration licensed Nirsevimab (Beyfortus), a long-acting monoclonal antibody for the prevention of respiratory syncytial virus (RSV) in infants and young children. It is anticipated that the Advisory Committee on Immunization Practices (ACIP) will vote on potential recommendations for use of this product and its inclusion in the Vaccines for Children (VFC) program at the August 3rd ACIP meeting.

New codes listed above have been added in anticipation of potential recommendations.  More information to support integration into VFC, as well as details around vaccine codes, Clinical Decision Support for Immunization (CDSi), and any data collection requirements will be published as they become available.

2023/2024 Seasonal Influenza Codes and Crosswalk

This new format includes all seasonal influenza vaccines for the 2023/2024 season in a single Excel crosswalk table that provides the CVX, MVX, NDC Unit of Sale, NDC Unit of Use, and CPT (*) codes for each vaccine.

(*) Please note that the CPT codes shown for each vaccine crosswalk are not mapped to the NDC codes, but are mapped to the CVX codes shown.  These are reference CPT codes for vaccine categorization and are not intended to represent billable codes.

Download the Seasonal Influenza Crosswalk table

Influenza Vaccines for Season 2023/2024 (Northern Hemisphere)
CVX Code CVX Short Description Sale Proprietary Name Sale Labeler MVX Code Unit of Sale NDC11 Unit of Use NDC11 Presentation CPT Code CPT Description
149 influenza, live, intranasal, quadrivalent FluMist Quadrivalent MedImmune, LLC MED 66019-0310-10 66019-0310-01 APPLICATOR 0.2 mL 90672 Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use
150 Influenza, injectable, quadrivalent, preservative free Afluria Quadrivalent Seqirus PTY LTD. SEQ 33332-0323-03 33332-0323-04 SYRINGE, 0.5 mL 90686 Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use
150 influenza, injectable, quadrivalent, preservative free FLUARIX QUADRIVALENT GlaxoSmithKline Biologicals SA SKB 58160-0909-52 58160-0909-41 SYRINGE, 0.5 mL 90686 Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use
150 influenza, injectable, quadrivalent, preservative free Flulaval Quadrivalent ID Biomedical Corporation of Quebec IDB 19515-0814-52 19515-0814-41 SYRINGE, 0.5 mL 90686 Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use
150 influenza, injectable, quadrivalent, preservative free Fluzone Quadrivalent Northern Hemisphere Sanofi Pasteur Inc. PMC 49281-0423-50 49281-0423-88 SYRINGE, 0.5 mL 90686 Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use
158 influenza, injectable, quadrivalent, contains preservative Afluria Quadrivalent Seqirus PTY LTD. SEQ 33332-0423-10 33332-0423-11 VIAL, 5 mL, MULTI-DOSE 90687 Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.25 mL dosage, for intramuscular use
90688 Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use
158 influenza, injectable, quadrivalent Fluzone Quadrivalent Northern Hemisphere Sanofi Pasteur Inc. PMC 49281-0639-15 49281-0639-78 VIAL, 5 mL, MULTI-DOSE 90687 Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.25 mL dosage, for intramuscular use
90688 Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use
171 Influenza, injectable, MDCK, preservative free, quadrivalent Flucelvax Quadrivalent Seqirus Inc. SEQ 70461-0323-03 70461-0323-04 SYRINGE, 0.5 mL 90674 Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use
185 influenza, recombinant, quadrivalent,injectable, preservative free Flublok Quadrivalent Northern Hemisphere Sanofi Pasteur Inc. PMC 49281-0723-10 49281-0723-88 SYRINGE, 0.5 mL 90682 Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use
186 Influenza, injectable, MDCK, quadrivalent, preservative Flucelvax Quadrivalent Seqirus Inc. SEQ 70461-0423-10 70461-0423-11 VIAL, 5 mL, MULTI-DOSE 90756 Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use
197 influenza, high-dose, quadrivalent Fluzone High-Dose Quadrivalent Northern Hemisphere Sanofi Pasteur Inc. PMC 49281-0123-65 49281-0123-88 SYRINGE, 0.7 mL 90662 Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use
205 Influenza vaccine, quadrivalent, adjuvanted FLUAD QUADRIVALENT Seqirus, Inc. SEQ 70461-0123-03 70461-0123-04 SYRINGE, 0.5 ml 90694 Influenza virus vaccine, quadrivalent (aIIV4), inactivated, adjuvanted, preservative free, 0.5 mL dosage, for intramuscular use
Southern Hemisphere 2023 Influenza Season
CVX Code CVX Short Description Sale Proprietary Name Sale Labeler MVX Code Unit of Sale NDC11 Unit of Use NDC11 Presentation CPT Code CPT Description
200 influenza, Southern Hemisphere, pediatric, preservative free FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE Sanofi Pasteur Inc. PMC NA NA SYRINGE, 0.25 mL NA NA
201 influenza, Southern Hemisphere, preservative free FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE Sanofi Pasteur Inc. PMC 49281-0323-50 49281-0323-88 SYRINGE, 0.5 mL NA NA
202 influenza, Southern Hemisphere, quadrivalent, with preservative FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE Sanofi Pasteur Inc. PMC 49281-0355-15 49281-0355-78 VIAL, MULTI-DOSE, 5 mL NA NA
231 influenza, Southern Hemisphere, high-dose, quadrivalent FLUZONE High-Dose Quadrivalent Southern Hemisphere Sanofi Pasteur Inc. PMC 49281-0379-50 49281-0379-88 SYRINGE, .7 mL NA NA